{"id":"protease-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":null,"effect":"Lipid abnormalities (elevated cholesterol and triglycerides)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Drug interactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Protease inhibitors work by binding to and inhibiting protease enzymes that are essential for the life cycle of viruses (such as HIV or hepatitis C) or bacteria. By preventing protease activity, these drugs block the cleavage of viral or pathogenic polyproteins into functional components, thereby halting viral replication or bacterial proliferation. This mechanism has been particularly successful in treating retroviral infections and some viral hepatitis cases.","oneSentence":"Protease inhibitors block viral or bacterial protease enzymes, preventing the processing of viral or pathogenic proteins necessary for replication and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:17.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV infection (as part of antiretroviral therapy)"},{"name":"Hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT06679140","phase":"PHASE3","title":"A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-12-08","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":2330},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT05521438","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quoin Pharmaceuticals","startDate":"2022-06-23","conditions":"Netherton Syndrome","enrollment":30},{"nctId":"NCT05600062","phase":"NA","title":"Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2023-03-21","conditions":"Acute Respiratory Distress Syndrome","enrollment":48},{"nctId":"NCT07326592","phase":"PHASE4","title":"Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)","status":"NOT_YET_RECRUITING","sponsor":"CSL Behring","startDate":"2026-04-15","conditions":"Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema","enrollment":270},{"nctId":"NCT07013474","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-14","conditions":"COVID-19 Infection","enrollment":300},{"nctId":"NCT01983241","phase":"PHASE3","title":"Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2013-11","conditions":"Pulmonary Emphysema in Alpha-1 PI Deficiency","enrollment":345},{"nctId":"NCT04337450","phase":"PHASE2, PHASE3","title":"DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-04-22","conditions":"HIV Infections","enrollment":386},{"nctId":"NCT02796937","phase":"PHASE3","title":"Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency","status":"ENROLLING_BY_INVITATION","sponsor":"Grifols Therapeutics LLC","startDate":"2016-07","conditions":"Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency","enrollment":290},{"nctId":"NCT05271630","phase":"","title":"Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-04-20","conditions":"Multiple Myeloma","enrollment":69},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT04874428","phase":"PHASE1","title":"Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-05-19","conditions":"Liver Cirrhosis","enrollment":24},{"nctId":"NCT03256916","phase":"PHASE3","title":"Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix","status":"COMPLETED","sponsor":"Tata Memorial Hospital","startDate":"2018-01-16","conditions":"Carcinoma Cervix,Stage III","enrollment":348},{"nctId":"NCT05587894","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT03363464","phase":"","title":"Comparative Effectiveness of Empagliflozin in the US","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2017-10-16","conditions":"Diabetes Mellitus, Type 2","enrollment":230000},{"nctId":"NCT07406217","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","status":"RECRUITING","sponsor":"Calmy Alexandra","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT07099677","phase":"NA","title":"Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk","status":"RECRUITING","sponsor":"Abant Izzet Baysal University","startDate":"2025-08-01","conditions":"Hypertension, Fall Risk, Postural Balance","enrollment":186},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT06863545","phase":"NA","title":"Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-22","conditions":"Coronary Artery Disease, CT Angiography, PCSK9","enrollment":3596},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT06797999","phase":"PHASE1, PHASE2","title":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Adcendo ApS","startDate":"2025-06-05","conditions":"Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma","enrollment":270},{"nctId":"NCT07365592","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT07157007","phase":"PHASE2","title":"Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19","status":"RECRUITING","sponsor":"Traws Pharma, Inc.","startDate":"2025-09-16","conditions":"COVID - 19","enrollment":90},{"nctId":"NCT07332156","phase":"","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"Type 2 Diabetes, COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)","enrollment":21692},{"nctId":"NCT05832229","phase":"PHASE2","title":"Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-12-07","conditions":"Cirrhosis, Cirrhosis, Liver, Cirrhosis Early","enrollment":256},{"nctId":"NCT07315191","phase":"PHASE4","title":"Finerenone Therapy for Pediatric HSPN With Mild Proteinuria","status":"RECRUITING","sponsor":"Capital Institute of Pediatrics, China","startDate":"2025-06-13","conditions":"Henoch Schönlein Purpura Nephritis","enrollment":116},{"nctId":"NCT00630058","phase":"PHASE1","title":"A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT00591214","phase":"PHASE1","title":"Safety and PK Study of MP-424 to Treat Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-12","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT00780416","phase":"PHASE3","title":"Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Hepatitis C","enrollment":189},{"nctId":"NCT00621296","phase":"PHASE2","title":"Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-01","conditions":"Hepatitis C","enrollment":15},{"nctId":"NCT07315139","phase":"NA","title":"Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-02-01","conditions":"Pentoxifylline, Inflammatory Markers, Non-Diabetic","enrollment":42},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07256197","phase":"PHASE3","title":"PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-01-01","conditions":"Aortic Stenosis, Calcific","enrollment":160},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT06263270","phase":"PHASE1","title":"Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee","status":"COMPLETED","sponsor":"Cytonics Corporation","startDate":"2024-06-01","conditions":"Osteoarthritis, Knee, Osteoarthritis","enrollment":19},{"nctId":"NCT07291050","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-12","conditions":"Advanced Cancer","enrollment":40},{"nctId":"NCT03696160","phase":"PHASE3","title":"The Late Presenter Treatment Optimisation Study","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2019-03-05","conditions":"HIV/AIDS","enrollment":447},{"nctId":"NCT05009992","phase":"PHASE2","title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-20","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma","enrollment":360},{"nctId":"NCT05485155","phase":"PHASE2","title":"Zemaira Eosinophilic Esophagitis Pilot Study","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2025-05-15","conditions":"Eosinophilic Esophagitis","enrollment":15},{"nctId":"NCT07285421","phase":"NA","title":"Renal and Vascular Phenotypic Characterization of Patients With Enamel Renal Syndrome Due to a Pathogenic Variant of the FAM20A Gene and Pathophysiological Study of Ectopic Calcifications","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-01","conditions":"Enamel Renal Syndrome","enrollment":30},{"nctId":"NCT04722887","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2021-08-13","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":17},{"nctId":"NCT07259512","phase":"PHASE4","title":"Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure","status":"RECRUITING","sponsor":"Evi Liliek Wulandari","startDate":"2025-06-30","conditions":"Chronic Kidney Disease, Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":80},{"nctId":"NCT05345717","phase":"PHASE1, PHASE2","title":"Novel Desensitization Kidney Transplantation","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2022-05-01","conditions":"Kidney Transplantation, End Stage Kidney Disease (ESRD)","enrollment":5},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT07256171","phase":"","title":"COAST Study - Cholesterol Optimization After Stroke","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-01-01","conditions":"Stroke (CVA) or Transient Ischemic Attack, Cerebral Hemorrhage","enrollment":500},{"nctId":"NCT05605093","phase":"PHASE3","title":"Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2022-12-23","conditions":"COVID-19","enrollment":602},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05768945","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-30","conditions":"Diabetes","enrollment":742670},{"nctId":"NCT05049616","phase":"PHASE4","title":"Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-10-18","conditions":"Hypertension in Pregnancy, Postpartum Preeclampsia","enrollment":70},{"nctId":"NCT03805789","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2019-03-27","conditions":"Acute-graft-versus-host Disease","enrollment":222},{"nctId":"NCT03910660","phase":"PHASE1, PHASE2","title":"A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.","status":"COMPLETED","sponsor":"BioXcel Therapeutics Inc","startDate":"2019-02-12","conditions":"Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma","enrollment":98},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT05214573","phase":"","title":"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-01","conditions":"Type 2 Diabetes, Cardiac Disease","enrollment":386301},{"nctId":"NCT06212661","phase":"","title":"Migraine Medication Effects on Urinary Symptoms","status":"ENROLLING_BY_INVITATION","sponsor":"The Cleveland Clinic","startDate":"2024-04-05","conditions":"Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders","enrollment":200},{"nctId":"NCT06928051","phase":"PHASE2","title":"A Study of S-892216 in Participants With COVID-19","status":"COMPLETED","sponsor":"Shionogi","startDate":"2025-06-06","conditions":"COVID-19","enrollment":282},{"nctId":"NCT07198191","phase":"","title":"SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2014-09-01","conditions":"Acute Myocardial Infarction (AMI), Type 2 Diabetes Mellitus (T2DM)","enrollment":200000},{"nctId":"NCT01737047","phase":"","title":"The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-04-01","conditions":"HIV Positive, Ageing","enrollment":1377},{"nctId":"NCT05733351","phase":"PHASE1","title":"Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2023-08-03","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":4},{"nctId":"NCT07171619","phase":"PHASE1","title":"Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat","status":"RECRUITING","sponsor":"SpringWorks Therapeutics, Inc.","startDate":"2025-09-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT06878066","phase":"PHASE3","title":"Thrombolysis in Factor Xa-inhibitors Trial","status":"RECRUITING","sponsor":"Guri Hagberg","startDate":"2025-03-14","conditions":"Stroke, Stroke (in Patients With Atrial Fibrillation), Ischemic Stroke","enrollment":300},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT04167514","phase":"PHASE3","title":"Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2020-01-09","conditions":"Graft Versus Host Disease (GVHD)","enrollment":136},{"nctId":"NCT07125664","phase":"PHASE2","title":"Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study)","status":"NOT_YET_RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2025-10-01","conditions":"Acute Exacerbation Chronic Obstructive Pulmonary Disease","enrollment":36},{"nctId":"NCT05977140","phase":"PHASE1","title":"CDI-988 Safety Study in Healthy Participants","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2023-09-27","conditions":"Healthy Volunteers","enrollment":116},{"nctId":"NCT06270394","phase":"NA","title":"FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Anhui Medical University","startDate":"2022-04-28","conditions":"Malignant Tumors, Positron-Emission Tomography","enrollment":22},{"nctId":"NCT05856331","phase":"PHASE2","title":"Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-12","conditions":"Alpha 1-Antitrypsin Deficiency, Emphysema","enrollment":99},{"nctId":"NCT07098897","phase":"PHASE3","title":"To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2024-08-01","conditions":"IgA Nephropathy (IgAN)","enrollment":150},{"nctId":"NCT06710158","phase":"PHASE1","title":"Study of SC-102 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Tianjin ConjuStar Biologics Co., Ltd.","startDate":"2024-12-05","conditions":"Advanced Solid Cancers","enrollment":120},{"nctId":"NCT06146374","phase":"PHASE1","title":"Safety Study of SLV213 for the Treatment of COVID-19.","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-09","conditions":"COVID-19","enrollment":16},{"nctId":"NCT06953466","phase":"PHASE2, PHASE3","title":"Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome","status":"RECRUITING","sponsor":"Quoin Pharmaceuticals","startDate":"2025-07","conditions":"Netherton Syndrome","enrollment":8},{"nctId":"NCT01935674","phase":"PHASE4","title":"Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2013-09","conditions":"HIV, Hypercholesterolaemia","enrollment":43},{"nctId":"NCT07051850","phase":"","title":"Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2025-07-14","conditions":"Multiple Myeloma, Relapsed, Multiple Myeloma (MM)","enrollment":174},{"nctId":"NCT00187512","phase":"","title":"SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2000-03","conditions":"HIV Infections","enrollment":2500},{"nctId":"NCT02652793","phase":"NA","title":"Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2015-11","conditions":"Human Immunodeficiency Virus","enrollment":31},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT06562582","phase":"PHASE4","title":"STunning in Acute Myocardial Infarction - BAS","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-01-06","conditions":"Myocardial Infarct","enrollment":120},{"nctId":"NCT07023016","phase":"PHASE2, PHASE3","title":"Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"National Heart Institute, Egypt","startDate":"2023-11-01","conditions":"Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD)","enrollment":515},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT04171219","phase":"PHASE2","title":"Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-19","conditions":"Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":31},{"nctId":"NCT06951243","phase":"PHASE2","title":"A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-05-06","conditions":"Advanced Extrapulmonary Neuroendocrine Cancer","enrollment":40},{"nctId":"NCT03464045","phase":"","title":"Empa PASS on Urinary Tract Malignancies","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":344995},{"nctId":"NCT04321096","phase":"PHASE1, PHASE2","title":"The Impact of Camostat Mesilate on COVID-19 Infection","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2020-04-04","conditions":"Corona Virus Infection","enrollment":206},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT06915350","phase":"","title":"The Role of Maspin in Colorectal Carcinoma, an Immunohistochemical Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-08","conditions":"Maspin in Colorectal Carcinoma","enrollment":50},{"nctId":"NCT06322953","phase":"PHASE3","title":"Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage","status":"RECRUITING","sponsor":"Walton Centre NHS Foundation Trust","startDate":"2025-03-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":1084},{"nctId":"NCT05789056","phase":"PHASE2, PHASE3","title":"Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome","status":"RECRUITING","sponsor":"Quoin Pharmaceuticals","startDate":"2023-03-14","conditions":"Netherton Syndrome","enrollment":20},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT02378805","phase":"","title":"Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","status":"RECRUITING","sponsor":"University Hospital Goettingen","startDate":"1995-07","conditions":"Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease","enrollment":800},{"nctId":"NCT06853951","phase":"PHASE3","title":"Cardioprotection on Chemotherapy-Induced Cardiotoxicity","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2023-07-18","conditions":"Cardiotoxicity","enrollment":30},{"nctId":"NCT06838286","phase":"","title":"Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":10000},{"nctId":"NCT06161688","phase":"PHASE2","title":"Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Timothy Henrich","startDate":"2024-04-09","conditions":"Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19","enrollment":40},{"nctId":"NCT03127631","phase":"NA","title":"A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients","status":"RECRUITING","sponsor":"McMaster University","startDate":"2015-10-21","conditions":"Prostate Cancer, Cardiovascular Disease","enrollment":6000},{"nctId":"NCT02398656","phase":"PHASE3","title":"A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-04-01","conditions":"Stroke, Acute","enrollment":1274},{"nctId":"NCT06796517","phase":"","title":"Immunotherapy in Lymphoma","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2024-06-26","conditions":"Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed","enrollment":72}],"_emaApprovals":[],"_faersSignals":[{"count":15,"reaction":"ANAEMIA"},{"count":11,"reaction":"RASH"},{"count":10,"reaction":"DIARRHOEA"},{"count":9,"reaction":"PYREXIA"},{"count":8,"reaction":"NAUSEA"},{"count":7,"reaction":"FATIGUE"},{"count":7,"reaction":"PNEUMONIA"},{"count":7,"reaction":"THROMBOCYTOPENIA"},{"count":6,"reaction":"HAEMOGLOBIN DECREASED"},{"count":6,"reaction":"HEADACHE"}],"_approvalHistory":[],"publicationCount":21643,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prezista® / Norvir®"],"phase":"marketed","status":"active","brandName":"Protease Inhibitor","genericName":"Protease Inhibitor","companyName":"Medical Research Council","companyId":"medical-research-council","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Protease inhibitors block viral or bacterial protease enzymes, preventing the processing of viral or pathogenic proteins necessary for replication and survival. Used for HIV infection (as part of antiretroviral therapy), Hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}